Author

Brian M. Mehling

Unknown affiliation - Cited by 3,874

Biography

Dr. Brian M. Mehling graduated from the Wright State University Boonshoft School of Medicine in 1996. He works in Hackensack, NJ and 1 other location and specializes in Orthopaedic Surgery. Dr. Mehling is affiliated with Good Samaritan Hospital Medical Center, Hackensack UMC At Pascack Valley, Hackensack University Medical Center, Meadowlands Hospital Medical Center, St Josephs Regional Medical Center and St Josephs Wayne Hospital.
Title
Cited by
Year
Microfluidic cell culture
M Mehling, S TayCurrent opinion in Biotechnology 25, 95-102, 2014201
414
2014
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis
L Kappos, M Mehling, R Arroyo, G Izquierdo, K Selmaj, V Curovic-Perisic, ...Neurology 84 (9), 872-879, 2015201
159
2015
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
M Mehling, TA Johnson, J Antel, L Kappos, A Bar-OrNeurology 76 (8 Supplement 3), S20-S27, 2011201
159
2011
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis
J Kuhle, D Leppert, A Petzold, A Regeniter, C Schindler, M Mehling, ...Neurology 76 (14), 1206-1213, 2011201
159
2011
Advances in oral immunomodulating therapies in relapsing multiple sclerosis
T Derfuss, M Mehling, A Papadopoulou, A Bar-Or, JA Cohen, L KapposThe Lancet Neurology 19 (4), 336-347, 2020202
93
2020
Antigen‐specific adaptive immune responses in fingolimod‐treated multiple sclerosis patients
M Mehling, P Hilbert, S Fritz, B Durovic, D Eichin, O Gasser, J Kuhle, ...Annals of neurology 69 (2), 408-413, 2011201
91
2011
The immune-metabolic basis of effector memory CD4+ T cell function under hypoxic conditions
S Dimeloe, M Mehling, C Frick, J Loeliger, GR Bantug, U Sauder, ...The Journal of Immunology 196 (1), 106-114, 2016201
85
2016
Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions
M Mehling, L Kappos, T DerfussCurrent neurology and neuroscience reports 11, 492-497, 2011201
79
2011
A microfluidic device for measuring cell migration towards substrate-bound and soluble chemokine gradients
J Schwarz, V Bierbaum, J Merrin, T Frank, R Hauschild, T Bollenbach, ...Scientific reports 6 (1), 36440, 2016201
77
2016
Locally triggered release of the chemokine CCL21 promotes dendritic cell transmigration across lymphatic endothelia
K Vaahtomeri, M Brown, R Hauschild, I De Vries, AF Leithner, M Mehling, ...Cell reports 19 (5), 902-909, 2017201
70
2017
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development
H Hegen, A Millonig, A Bertolotto, M Comabella, G Giovanonni, M Guger, ...Multiple Sclerosis Journal 20 (5), 577-587, 2014201
52
2014
Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis
H Gensicke, D Leppert, O Yaldizli, RLP Lindberg, M Mehling, L Kappos, ...CNS drugs 26, 11-37, 2012201
45
2012
Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy
M Mehling, S Fritz, P Hafner, D Eichin, T Yonekawa, T Klimkait, ...PLoS One 8 (11), e78532, 2013201
41
2013
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
H Hegen, I Adrianto, CJ Lessard, A Millonig, A Bertolotto, M Comabella, ...Neurology-Neuroimmunology Neuroinflammation 3 (2), 2016201
38
2016
Real-time tracking, retrieval and gene expression analysis of migrating human T cells
M Mehling, T Frank, C Albayrak, S TayLab on a Chip 15 (5), 1276-1283, 2015201
38
2015
Vedolizumab as a successful treatment of CTLA-4–associated autoimmune enterocolitis
AA Navarini, P Hruz, CT Berger, TZ Hou, C Schwab, A Gabrysch, ...Journal of Allergy and Clinical Immunology 139 (3), 1043-1046. e5, 2017201
33
2017
Nano-scale microfluidics to study 3D chemotaxis at the single cell level
C Frick, P Dettinger, J Renkawitz, A Jauch, CT Berger, M Recher, ...PloS one 13 (6), e0198330, 2018201
32
2018
Characteristics of autoantibodies targeting 14-3-3 proteins and their association with clinical features in newly diagnosed giant cell arteritis
A Kistner, MB Bigler, K Glatz, SB Egli, FS Baldin, FA Marquardsen, ...Rheumatology 56 (5), 829-834, 2017201
21
2017
Tissue Distribution Dynamics of Human NK Cells Inferred from Peripheral Blood Depletion Kinetics after Sphingosine‐1‐Phosphate Receptor Blockade
M Mehling, AV Burgener, V Brinkmann, GR Bantug, S Dimeloe, ...Scandinavian journal of immunology 82 (5), 460-466, 2015201
13
2015
Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis
Y Naegelin, M Rasenack, M Andelova, S Von Felten, B Fischer-Barnicol, ...Multiple sclerosis and related disorders 25, 14-20, 2018201
11
2018

Referred From: https://scholar.google.com/citations?user=Y4PZCHoAAAAJ&hl=en

Cited by
Citations 3874
h-index 28
i10-index 42
Recommended Journals
Open Access Journals